Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments

doi:10.4254/wjh.v8.i17.703

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14290)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-8) series.

Item

Count

PDF

1606

WORD

366

HTML

7210

Figures (1-9)

332

Tables (1-8)

202

Sum=9716

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

428

Download

908

Sum=1336

Publishing Process of This Article

Item

Count

Browse

1235

Download

2003

Sum=3238

Jun 18, 2016 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Hepatol. Jun 18, 2016; 8(17): 703-715
Published online Jun 18, 2016. doi: 10.4254/wjh.v8.i17.703

Full Size Figure Download Figure

Figure 6 Evolution of the median overall survival according to the NIACE score in hepatocellular carcinoma patients from a French multicenter study treated by transarterial chemoembolization (grey bars center 1, black bars center 2)[60]. TACE: Transarterial chemoembolization.

Citation: Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715
URL: https://www.wjgnet.com/1948-5182/full/v8/i17/703.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i17.703